CompanyDrug

Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review

CompanyDrug

Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China

CompanyDrug

Daiichi Sankyo’s Mirogabalin Nears China Market Entry with CDE Review

CompanyDrug

Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra

CompanyDrug

Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD

CompanyDeals

AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab

Policy / Regulatory

China’s NHC Releases Second National Drug Use Monitoring List

CompanyDeals

Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion

CompanyDeals

Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion

CompanyDrug

CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers

CompanyDeals

Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development

CompanyDrug

Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA